Irinotecan in Treating Children With Refractory or Progressive Solid Tumors

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: June 6, 2001
Last updated: June 25, 2013
Last verified: November 2004

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children who have refractory or progressive solid tumors.

Condition Intervention Phase
Unspecified Childhood Solid Tumor, Protocol Specific
Drug: irinotecan hydrochloride
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pediatric Phase I and Pharmacokinetic Study of Irinotecan

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: September 1998
Study Completion Date: January 2005
Detailed Description:


  • Determine the maximum tolerated dose and dose-limiting toxicity of irinotecan in children with refractory or progressive solid tumors.
  • Determine the pharmacokinetics of this drug and its metabolites (SN-38, SN-38G, and APC) administered with and without concurrent anticonvulsants in this patient population.
  • Determine the benefit this drug offers this patient population.

OUTLINE: This is a dose-escalation, multicenter study. Patients are accrued into stratum 1 initially and into stratum 2 if stratum 1 closes due to dose-limiting toxicity of myelosuppression or diarrhea. Patients on anticonvulsants will be accrued into stratum 3 and must meet the eligibility criteria for the stratum that is open (stratum 1 or stratum 2). (Stratum 1 closed as of 2002-09-15).

Patients receive irinotecan IV over 90 minutes weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of irinotecan until the maximum tolerated dose (MTD) with and without anticonvulsants is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed every 6 months for 4 years and then annually thereafter.

PROJECTED ACCRUAL: Approximately 20-25 patients will be accrued for this study.


Ages Eligible for Study:   1 Year to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed solid tumor refractory to standard therapy or for which no known effective therapy exists

    • Brain tumors eligible

      • Histologic verification waived for brain stem gliomas
  • Evaluable disease
  • No bone marrow involvement



  • 1 to 21

Performance status:

  • Karnofsky 50-100% (over age 10)
  • Lansky 50-100% (age 10 and under)

Life expectancy:

  • At least 8 weeks


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 8 g/dL


  • Bilirubin less than 1.5 mg/dL
  • SGPT less than 5 times normal


  • Creatinine normal OR
  • Glomerular filtration rate at least 70 mL/min


  • No uncontrolled infection
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 6 months after study


Biologic therapy:

  • At least 6 months since prior autologous bone marrow transplantation (BMT) (not including stem cell rescue after high-dose chemotherapy)
  • At least 1 week since prior growth factors
  • No prior BMT with total body irradiation (stratum I)
  • No prior BMT with or without total body irradiation (stratum 2)
  • No prior allogeneic BMT (all strata)
  • No concurrent sargramostim (GM-CSF)
  • No other concurrent prophylactic growth factor support during the first course of therapy


  • At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)
  • No prior irinotecan
  • No more than 2 prior multi-agent chemotherapy regimens (stratum 2)
  • No other concurrent chemotherapy

Endocrine therapy:

  • Concurrent dexamethasone allowed if on stable or decreasing dose for at least 2 weeks prior to study


  • At least 6 months since prior craniospinal radiotherapy or radiotherapy to 50% or more of the pelvis
  • At least 6 weeks since other prior substantial bone marrow radiotherapy
  • No prior central axis radiotherapy, pelvic radiotherapy, and/or total abdominal radiotherapy (stratum 2)


  • Not specified


  • Recovered from all prior therapy
  • No other concurrent investigational agents
  • Concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital, carbamazepine) allowed if on stable dose for at least 2 weeks prior to study (stratum 3)
  • Concurrent valproic acid allowed if combined with another enzyme inducing anticonvulsant drug (stratum 3)
  Contacts and Locations
Please refer to this study by its identifier: NCT00016861

United States, Texas
Texas Children's Cancer Center
Houston, Texas, United States, 77030-2399
Sponsors and Collaborators
Texas Children's Cancer Center
Study Chair: Susan M. Blaney, MD Texas Children's Cancer Center
  More Information

Additional Information:
No publications provided Identifier: NCT00016861     History of Changes
Other Study ID Numbers: TCCC-H-6957, CDR0000068568, TCCC-GCRC-0654, NCI-V01-1654
Study First Received: June 6, 2001
Last Updated: June 25, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
unspecified childhood solid tumor, protocol specific

Additional relevant MeSH terms:
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 17, 2014